Bausch + Lomb Corp.’s latest results and its outlook for sales growth in the eye care and vision health space for its consumer health lines as its well Rx and medtech products boost the Canadian firm’s price tag in a potential divestment by majority owner Bausch Health Companies Inc.
Bausch + Lomb Results Enhance Acquisition Image
Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.
More from Earnings
• By
The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.
• By
Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.
• By
Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.